To view this email as a web page, click here.

ONCOLOGY: Practical, Peer-Reviewed Perspectives

Volume 33, Number 4

Click here to view the full table of contents.

Click here for the Digital Edition

REVIEW ARTICLE

Novel Targets and Precision Medicine for Prostate Cancer—Part 2: Tumor Profiling and Personalized Therapy in Patients With Castration-Resistant Prostate Cancer

Bryden Considine, DO, and Daniel P. Petrylak, MD
In this article, we review the current use of and future direction for genetic testing and tumor profiling in patients with metastatic castration-resistant prostate cancer.

INSIGHTS FROM AN ONCOLOGY PHARMACIST

Regorafenib for Metastatic Colorectal Cancer: Common Toxicities and Prevention Strategies

Amber Draper, PharmD, BCOP
An oncology pharmacist discusses how to prevent and treat the toxicities from regorafenib for the treatment of colorectal cancer.

Read more

One FDA-Approved test analyzes 324 cancer-related genes
FoundationOne^®CDx analyzes all recommend genomic biomarkers for solid tumors, including companion diagnostic indications with direct paths to therapy. This one test can help guide therapy selection and clinical trial options for more patients. Read more

This is a post-only, outbound email. Please do not reply to this email as we will be unable to respond to your reply. Please use the links provided if you have questions or concerns regarding this email or your subscription.